MacroGenics | MGNX - Ordinary Share Capital


MacroGenics reported $63.32M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Genmab DKK 61.62M 52K Dec/2025
Geron USD 640.9M 2.54M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
MacroGenics USD 63.32M 60K Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Xencor USD 74.06M 2.19M Mar/2026